Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Radiation Therapy Plus Hyperbaric Oxygen in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Hyperbaric oxygen
 may increase the effectiveness of radiation therapy. Combining hyperbaric oxygen with
 radiation therapy may be an effective treatment for glioblastoma multiforme.

 PURPOSE: Phase I/II trial to study the effectiveness of combining radiation therapy with
 hyperbaric oxygen in treating patients who have newly diagnosed glioblastoma multiforme.
OBJECTIVES: I. Determine the feasibility and toxicity of hyperbaric oxygen combined with
 conformal radiotherapy in patients with newly diagnosed glioblastoma multiforme. II.
 Determine the efficacy of this regimen in terms of radiographic tumor response, time to tumor
 progression, and survival in these patients.

 OUTLINE: Within 2 weeks after surgery, patients receive hyperbaric oxygen over 90 minutes
 once daily, followed by conformal radiotherapy twice daily 5 days a week for 17 days in the
 absence of unacceptable toxicity. Patients are followed within 2 weeks and then every 2
 months thereafter.

 PROJECTED ACCRUAL: A total of 5-10 patients will be accrued for this study within 1 year.
DISEASE CHARACTERISTICS: Histologically proven newly diagnosed glioblastoma multiforme
 Measurable residual tumor by MRI after biopsy or craniotomy

 PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 70-100% Life
 expectancy: More than 8 weeks Hematopoietic: Not specified Hepatic: Not specified Renal:
 Not specified Pulmonary: No severe pulmonary disease (e.g., emphysema with carbon dioxide
 retention) No untreated pneumothorax Other: Not pregnant or nursing Negative pregnancy test
 Fertile patients must use effective contraception No other malignancy within the past 5
 years except epithelial skin cancer No psychological, familial, sociological, or
 geographical conditions that would preclude study No intractable seizure disorder

 PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior or
 concurrent bleomycin Endocrine therapy: Not specified Radiotherapy: No prior cranial
 radiotherapy Surgery: See Disease Characteristics Other: No other prior therapy, including
 adjuvant therapy, for glioblastoma multiforme